The emergence of Retatrutide ZPHC, at a dosage of 120mg, is creating considerable interest within the healthcare community. This novel dual GIP and GLP-1 receptor medication seems to deliver impressive improvements in weight shedding compared to current therapies. Early clinical trials have shown